Long-Term Safety and Efficacy of Pars Plana Vitrectomy for Uveitis: Experience of a Tertiary Referral Centre in the United Kingdom

Author:

El Faouri Muhannd12,Ally Naseer1ORCID,Lippera Myrta1ORCID,Subramani Siddharth3,Moussa George1ORCID,Ivanova Tsveta1,Patton Niall1,Dhawahir-Scala Felipe1,Rocha-de-Lossada Carlos4567ORCID,Ferrara Mariantonia18,Jalil Assad1ORCID

Affiliation:

1. Manchester Royal Eye Hospital, Oxford Road, Manchester M13 9WL, UK

2. Faculty of Medicine, The Hashemite University, P.O. Box 330127, Zarqa 13133, Jordan

3. Khoo Teck Puat Hospital, Singapore 768828, Singapore

4. Qvision, Opththalmology Department, VITHAS Almería Hospital, 04120 Almería, Spain

5. Ophthalmology Department, VITHAS Málaga, 29016 Málaga, Spain

6. Regional Universityu Hospital of Malaga, Plaza del Hospital Civil, 29010 Málaga, Spain

7. Surgery Department, University of Sevilla, 41009 Seville, Spain

8. School of Medicine, University of Málaga, 29016 Málaga, Spain

Abstract

Aim: To evaluate the effectiveness of pars plana vitrectomy (PPV) without macular intervention on uveitis eyes with persistent vitreous inflammation/opacities in terms of visual acuity (VA), intraocular inflammation and macular profile. Methods: We carried out a single-center retrospective study of patients with uveitic eyes that underwent PPV without intervention on the macula due to persistent vitreous inflammation/opacities. The primary outcome measures were best-corrected visual acuity (BCVA), intraocular inflammation and macular profile at 3, 12 and 24 months after surgery. Results: Twenty-seven eyes of twenty-six patients were analyzed. Overall, 77.8% had an improvement of VA (55% by 0.3 LogMAR or more); 62.5% of patients had no intraocular inflammation, and the number of patients on systemic steroids and second-line immunosuppressives was reduced by 26% at 12 months; 87.5% of patients had resolution of macular oedema at 12 months. Conclusion: PPV for persistent vitreous inflammation/opacities is safe and effective, showing beneficial outcomes in terms of improvement of BCVA and the reduction in inflammation.

Publisher

MDPI AG

Subject

General Medicine

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3